Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH 2017 | Upcoming clinical trials for venetoclax chemotherapy combinations for AML

Marina Konopleva • 5 Oct 2017

ESH 2017

Acute Myeloid Leukemia Cytarabine Fludarabine G-CSF Idarubicin Venetoclax

This is an exciting time for new acute myeloid leukemia (AML) therapies, particularly combination treatments. In this video, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, discusses planned upcoming clinical trials for new venetoclax chemotherapy combinations for AML, including that with FLAG-IDA (NCT03214562). Dr Konopleva explains why she is hopeful that these regimens will improve treatment and mentions the combination therapies that she hopes to work on in the future. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).

Advancements in AML: an update from ASH 2023

Marina Konopleva • 8 Dec 2023

The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML

Marina Konopleva • 8 Dec 2023

10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML

Marina Konopleva • 8 Dec 2023

Targeting mitochondrial metabolism to eradicate MRD in AML

Marina Konopleva • 8 Dec 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?

Raynier Devillier • 15 Apr 2024

The role of the bone marrow microenvironment in hematological malignancies

Manja Wobus • 17 Apr 2024